AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03088306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard analgesia use [Hydromorphone]
Description: A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
Study NCT03088306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard analgesia use [Volatile Anesthesia]
Description: A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
Study NCT03088306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard analgesia use [Fentanyl]
Description: A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
Study NCT03088306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal pain management [Acetaminophen + Gabapentin]
Description: Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
Study NCT03088306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal pain management [Fentanyl]
Description: Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
Study NCT03088306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal pain management [Intravenous Ketamine]
Description: Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
Study NCT03532464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline
Description: The patients in the doxycycline group take one tablet of 100 mg twice a day for seven days.
Study NCT03088306 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal pain management [Valium + Gabapentin]
Description: Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
Study NCT04035707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: using rocuronium as a relaxants during general anaesthesia
Study NCT04035707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: general volatile anaesthesia
Description: method of anaesthesia
Study NCT01992926 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interactive educational intervention
Description: Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
Study NCT01364506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water aerobic exercise
Description: The hydrotherapy program of Prevedel et al.14 was used. One-hour sessions, led by a physiotherapist under the supervision of an obstetrician, were held three times a week in an indoor swimming-pool heated at 28oC-32oC, and consisted of exercises of moderate intensity (60-70% of maximum heart rate). Subgroups of up to 10 subjects participated in each session. Sessions were offered at different times of the day (morning, afternoon, and evening).~The exercises included 5 phases: stretching, warm up, endurance training, strength training and relaxation with breathing exercises, in accordance with the recommendations of ACOG11.
Study NCT04183868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: 10 mg tablet daily
Study NCT00681421 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: URLC10, VEGFR1 and VEGFR2
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Study NCT04183868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride 2 mg
Description: starting dose: 2 mg tablet daily, 1 mg for lunch and 1 mg for dinner, can undergo to up-titration of glimepiride to a maximum of 6 mg daily
Study NCT01857570 — intervention group
Intervention type: RADIATION
Intervention: Volume Computed Tomography of the wrist and carpus
Study NCT00300976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle consultation: weight control, diet, exercise
Description: Behavioral: Lifestyle modification including weight control, with the goal of BMI 22.~Drug: Drugs are added in a stepwise manner to control blood glucose, blood pressure and lipid metabolism, using mainly hypoglycemic drugs, ACEI/ARB and statins, respectively. Management goals are: HbA1c \< 6.2%, BP \< 120/75 mmHg, HDL-C 40 mg/dL , LDL-C \< 80 mg/dL, TG \< 120 mg/dL.~Follow-up study (Not provided)
Study NCT00300976 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle consultation: weight control, diet, exercise
Description: Behavioral and Drug: The physician in charge is to administer appropriate therapy in accordance with the Guidelines.~Follow-up study (Not provided)
Study NCT00371748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté-SR
Description: Paclitaxel-Eluting Coronary Stent, 2.25 mm
Study NCT00371748 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TAXUS™ Express2
Description: Paclitaxel-Eluting Coronary Stent System
Study NCT00371748 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Express2
Description: Coronary Stent System
Study NCT03517410 — intervention group
Intervention type: OTHER
Intervention: Smart phone use
Description: Patients will be asked to use the smart phone while seated for either: (1) 10 minutes or (2) 30 minutes.
Study NCT00749450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study NCT00749450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00749450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00365924 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Forteo
Description: Open label single arm study with Forteo as an intervention
Study NCT05293184 — intervention group
Intervention type: OTHER
Intervention: Observational study only
Study NCT02434562 — intervention group
Intervention type: OTHER
Intervention: Serum (with or without urine) samples
Study NCT02258893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NO2 Scrubber
Description: an NO2 scrubber that removes NO2 and particles
Study NCT02524002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Accel Gel
Description: Accel Gel by PacificHealth Labs in Matawan, NJ.
Study NCT02280980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oculomotor and Gaze Stability Exercises
Description: Daily oculomotor and gaze stability exercises, twice a day, for three weeks
Study NCT02524002 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Usual clear diet
Description: Usual clear liquids
Study NCT04063592 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Residual limb revision
Description: Surgical procedure involving construction of agonist-antagonist myoneural interfaces (AMIs)
Study NCT01736371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Sevoflurane
Description: In this group of patients, the maintenance of anesthesia is done by 1% sevoflurane + propofol infusion. Propofol infusion is adjusted according to the Bispectral Index.
Study NCT01736371 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Propofol
Description: In this group the maintenance of anesthesia is maintained by only propofol infusion.
Study NCT01736371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: In this group only sevoflurane was used for maintenance of anesthesia. the dose of sevoflurane is adjusted to maintain Bispectral Index within 45 and 55.
Study NCT03785964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat oral tablet
Description: Nirogacestat tablet
Study NCT03015051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Study NCT03015051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Study NCT03785964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Sugar pill manufactured to mimic nirogacestat 50 mg tablet
Study NCT03688516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manipulation of valence and modality
Description: mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
Study NCT03688516 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Manipulation of valence and modality
Description: mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
Study NCT00807053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide HFA
Description: 75 mcg Ciclesonide HFA versus Placebo
Study NCT00807053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide HFA
Description: 150 mcg Ciclesonide HFA versus Placebo
Study NCT00807053 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide HFA
Description: 300 mcg Ciclesonide HFA versus Placebo
Study NCT00807053 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03688516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spatial and recognition memory
Description: mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
Study NCT03688516 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Spatial and recognition memory
Description: mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
Study NCT03688516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Source and content memory
Description: mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
Study NCT03688516 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Source and content memory
Description: mnemic task with a phase of encoding negative, positive and neutral stimuli, will be proposed followed by an immediate recovery phase, composed of a recall task followed by a recognition task
Study NCT03124836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Oximeter Sensor
Study NCT03374540 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: 15/20 mg
Study NCT03374540 — intervention group
Intervention type: DRUG
Intervention: Vitamin K antagonist (VKA)
Description: Individually adjusted dose
Study NCT01991522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Curriculum Group
Study NCT01991522 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed learning group
Study NCT01162902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem treated group
Description: Diltiazem 180mg for 9 months
Study NCT01162902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol treated group
Description: Bisoprolol 5mg for 9 months
Study NCT01162902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Candesartan treated group
Description: Candesartan 32mg for 9 months
Study NCT02155335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prefilled Syringe delivery of Golimumab
Description: Golimumab 50 mg solution for subcutaneous injection using prefilled syringe
Study NCT02155335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smartject Device delivery of Golimumab
Description: Golimumab 50 mg solution for subcutaneous injection using Smartject Device.
Study NCT03050879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Tracer
Description: Laparoscopic gastrectomy with lymph node dissection for gastric cancer using Indocyanine Green Tracer
Study NCT03050879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green Tracer
Description: Laparoscopic gastrectomy with lymph node dissection for gastric cancer using Indocyanine Green Tracer
Study NCT04377607 — intervention group
Intervention type: OTHER
Intervention: File scanning
Description: RBC, HGB, HCT, MCH, MCV, MCHC, WBC values will be noted in the hemogram test performed at the time of initial admission
Study NCT00302003 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy
Study NCT00302003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00302003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00302003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study NCT00302003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00302003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Description: Given IV
Study NCT00302003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV
Study NCT00302003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV
Study NCT00302003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide phosphate
Description: Given IV
Study NCT00302003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00302003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT00302003 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or subcutaneously
Study NCT00283439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 531
Description: Planned Cohorts:~1. 100 mcg,~2. 300 mcg,~3. 700 mcg,~4. 1000 mcg;~   Optional Cohorts:~5. cohort expansion,~6. schedule change,~7. new dose
Study NCT02047799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Calcitriol (1000 UI)
Study NCT02047799 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Placebo
Study NCT02258893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEPA filter
Description: a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
Study NCT02258893 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles
Study NCT02950831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerometry
Description: Record of activity levels using a wrist worn accelerometer
Study NCT04591782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PomJuice
Description: Drink 8 oz pomegranate juice
Study NCT04591782 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Water
Description: Drink 8 oz water
Study NCT04591782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar Water
Description: Drink 8 oz of water with 18.6 g of glucose + 18.3 g of fructose dissolved in
Study NCT00993382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celivarone
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT00993382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT00993382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo
Description: Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake
Study NCT00993382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake
Study NCT00993382 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Pharmaceutical form: capsule~Route of administration: oral~Matching placebo added to active drug if any for a total of 3 capsules per intake
Study NCT03539666 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diet
Description: dietary patterns
Study NCT03783026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Tablets for oral administration
Study NCT02445768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive multisensory rehabilitation
Study NCT01012765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)
Study NCT03640338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold-Therapy System
Description: After surgery, participants assigned to this group will receive the cold-therapy system to use at the hospital and during the first 2 weeks following discharge.
Study NCT01012765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
Study NCT00943332 — intervention group
Intervention type: PROCEDURE
Intervention: femur fracture repair
Description: all participants will have undergone surgical intervention to repair a femur fracture, the investigators will simply be collecting data after the procedure; participants will not be consented until after the procedure
Study NCT03022370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping Stones and Creating Futures
Description: Stepping Stones consists of 10 sessions. It seeks to strengthen relationships and to transform views on gender and in the process impact on exposure to, or participation in, gender-based violence and HIV risk. These cover gender and peer influences our actions; sex and love; conception and contraception; STIs and HIV; safer sex and condoms; GBV; motivations for behaviour (including influences of alcohol and poverty); and communication skills.~Creating Futures is a facilitated group intervention of eleven sessions. It seeks to strengthen livelihoods. The key sessions include: setting medium term livelihood goals, the need for assets and coping with crises; social resources for livelihoods (trust and community participation); getting and keeping jobs; and savings and spending.
Study NCT05976100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 once orally
Description: Volunteers take 1 capsule (200 mg) of NIOCH-14 as a single oral dose.
Study NCT05976100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIOCH-14, 200 mg capsule: 3 capsules (200 mg each) of NIOCH-14 once orally. (Total 600 mg NIOCH-14 per day)
Description: Volunteers take 3 capsules (200 mg each) of NIOCH-14 as a single oral dose. (Total 600 mg NIOCH-14 per day)
Study NCT05976100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIOCH-14, 200 mg capsule: 6 capsules (200 mg each) of NIOCH-14 per day orally. (Total 1200 mg NIOCH-14 per day)
Description: Single 1200-mg oral dose. (1200-mg dose of the drug is administered by 600 mg twice a day at 8-00 and 20-00 in the hospital and presence of a clinical investigator or a nurse).
Study NCT05976100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIOCH-14, 200 mg capsule: 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days
Description: Volunteers take 1 capsule (200 mg) of NIOCH-14 a day orally for 6 days.